Privium Fund Management B.V. Makes New Investment in enGene Holdings Inc. $ENGN

Key Points

• Privium Fund Management B.V. acquired a new 352,087‑share position in enGene (NASDAQ:ENGN) in Q4 valued at about $3.18 million, representing roughly 0.6% of Privium’s portfolio and 0.53% of enGene outstanding.
• enGene recently opened at $7.89 with a market cap of ~$528.6M and a 12‑month range of $2.65–$12.25; it reported quarterly EPS of -$0.44 (beating estimates) and carries a consensus "Moderate Buy" rating with an average target of $22.69.

Privium Fund Management B.V. acquired a new position in shares of enGene Holdings Inc. (NASDAQ:ENGN - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 352,087 shares of the company's stock, valued at approximately $3,179,000. enGene makes up approximately 0.6% of Privium Fund Management B.V.'s portfolio, making the stock its 26th biggest holding. Privium Fund Management B.V. owned 0.53% of enGene as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Cresset Asset Management LLC acquired a new position in enGene during the second quarter worth $36,000. Raymond James Financial Inc. raised its stake in enGene by 383.6% during the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company's stock worth $68,000 after acquiring an additional 7,932 shares in the last quarter. Paloma Partners Management Co acquired a new position in enGene during the second quarter worth $38,000. PFS Partners LLC raised its stake in enGene by 22.2% during the fourth quarter. PFS Partners LLC now owns 11,000 shares of the company's stock worth $99,000 after acquiring an additional 2,000 shares in the last quarter. Finally, Hudson Bay Capital Management LP acquired a new position in enGene during the third quarter worth $76,000. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Price Performance

Shares of ENGN stock opened at $7.89 on Wednesday. The stock has a 50-day moving average price of $7.78 and a 200 day moving average price of $8.36. The company has a quick ratio of 11.75, a current ratio of 11.75 and a debt-to-equity ratio of 0.09. The firm has a market cap of $528.55 million, a price-to-earnings ratio of -3.51 and a beta of -0.02. enGene Holdings Inc. has a 12 month low of $2.65 and a 12 month high of $12.25.

enGene (NASDAQ:ENGN - Get Free Report) last announced its quarterly earnings data on Monday, March 9th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.11. Research analysts expect that enGene Holdings Inc. will post -2.06 EPS for the current year.

Analyst Upgrades and Downgrades

ENGN has been the topic of several research analyst reports. Raymond James Financial restated a "strong-buy" rating and set a $27.00 target price on shares of enGene in a report on Monday, March 9th. Wall Street Zen cut enGene from a "hold" rating to a "sell" rating in a report on Saturday, April 18th. HC Wainwright restated a "buy" rating and set a $25.00 target price on shares of enGene in a report on Monday, March 9th. Guggenheim restated a "buy" rating on shares of enGene in a report on Tuesday, March 10th. Finally, Jefferies Financial Group initiated coverage on enGene in a report on Friday, January 30th. They set a "buy" rating and a $28.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $22.69.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Want to see what other hedge funds are holding ENGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for enGene Holdings Inc. (NASDAQ:ENGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.